

Author Index to Volume 12

Aarnaes, S.L., 269
Ackerman, V.P., 153S
Adams, M.A., 181
Agy, M.B., 303
Ajello, L., 21
Akalin, E., 185S
Akhter, J., 291
Aldridge, K.E., 1S, 45, 165, 221, 489
Alexander, W., 123
Allen, S.D., 413, 489
Amsterdam, D., 157
Anhalt, J.P., 463
Arbo, A., 147S
Armstrong, D., 517
Aujard, Y., 87
Ayers, L.W., 413
Bale, M., 337
Balentine, L.T., 189
Balfour Jr., H.H., 288
Balows, A., 289, 455, 525
Bandelloni, R., 53S
Barg, N.L., 357
Barry, A.L., 81, 143, 279, 381, 385, 413,
 495
Bartlett, K.R., 437
Baskerville, A.J., 65S
Beam Jr., T., 157
Bergstrom, R., 73
Bermudez, L.M., 17S
Bianchini, H.N., 45S
Bindra, R., 315
Bivins, B.A., 113
Blumberg, D.A., 351
Bodey, G.P., 209S
Bostick, C.C., 287
Brackman, M.A., 449
Brion, F., 87
Burdick, C., 189
Cabezudo, I., 337
Calikoglu, A.S., 185S
Canawati, H.N., 33
Canupp, K.C., 433
Carlson, L.C., 303
Cassell, G.H., 193, 433
Castrillon de P., L., 51S
Chaffin, D.O., 445
Chan, J., 193
Chang, S.T., 175S
Chan-Thim, J., 473
Chapis, C., 129
Chen, C.-M., 179S
Cherry, J.D., 351
Chin, N.-X., 283, 343, 477
Chretien, P., 87
Chu, M.-L., 179S
Chung, H.Y., 175S
Clark, N.C., 13
Cleary, T., 193
Cleri, D.J., 9
Clynes, N., 257
Collaborative Antimicrobial Susceptibility
 Testing Group, The, 413
Congeni, B.L., 287
Conville, P.S., 217, 309, 401
Cooksey, R.C., 13
Cordin, X., 139S
Coyle, M.B., 303
Crane, D., 288
Criqui, C., 87
Crots, L., 113
Cunha, B.A., 291
Curtis, S.E., 315
Dahlgren, J., 21S
Dalton, M.T., 521
D'Amato, R.F., 9
Dascal, A., 473
Dean, D., 133
Debbia, E., 53S
Degagne, P.A., 437, 83S
de la Maza L.M., 269
Dirksen, C.L., 288
DiVincenzo, C.A., 13S
Dubois, J., 89S
Duffy, L.B., 433
Dugger, K.O., 199
Dulworth, J.K., 449
Dupont, H.L., 139
Eades, S.C., 57
Ecevit, Z., 185S
Edberg, S.C., 129
Edelstein, M.A.C., 93S
Edelstein, P.H., 93S
Eliopoulos, G.M., 149, 481
Elwing, H., 171
Erickson, R.C., 235
Faro, S., 189S
Fath, J.J., 113
Fedorko, D.P., 463
Felmingham, D., 65S
Fernandes, C.J., 153S
Fernandez, A., 45S
Ferraro, M.J., 481
Ferrero, S.M., 45S
Fikrig, E., 357
Finegold, S.M., 117S
Fiss, E.F., 211
Folds, J.D., 319
Forward, K.R., 205, 437
Friis, H., 67
Fuchs, P.C., 81, 413, 489
Galgiani, J.N., 199
Gallo, P., 129
Gardiner, R.V., 271, 385
Gaudet, E.A., 93S
Gavan T.L., 413
Gebbia, K., 221
Gelfand, M.S., 421
Gerarden, T., 1, 467
Gerlach, E.H., 101, 413, 489
Germer, J.J., 463
Gibbons, A., 73
Gibson, C.B., 235, 449
Gleaves, C.A., 315
Golper, T.A., 457
Gomez, C., 51S
Goodpasture, H.C., 101
Gorzyński, E., 157
Grabowski, M., 77S
Gray, L.D., 275
Griffis, J., 327
Grogan, J.T., 421
Grüneberg, R.N., 65S
Gunel, M., 185S
Gvazdinskas, L.C., 107, 253
Haas, M.J., 421
Haldane, D.J.M., 521
Hall, N., 295
Hammill, H.A., 189S
Harrison, B.B., 107
Hasegawa, H., 215S
Helms, C., 295
Henderberg, A., 1S, 221
Herrmann, K.L., 333
Hii, J., 517
Hildebrand, A.R., 235, 449
Hilliard, J.K., 333
Hinthorn, D.R., 17
Ho, D.H., 209S
Hoban, D., 77, 83S
Hochstein, L., 9
Hoeprich, P.D., 17
Hoffmann, P.F., 235
Holland, M.D., 457
Hollis, R., 295
Holmes, G.P., 333
Horiuchi, A., 215S
Hörnsten, E.G., 171
Horst, H.M., 113
Houston, A., 1
Hsu, C.-Y., 179S
Huang, L.-M., 179S
Hunt, T.L., 181
Hursh, D.A., 315
Icenogle, J., 197
Ikemoto, H., 239S
Ilstrup, D.M., 275
Inderlied, C.B., 17S
Ingaramo, R.A., 45S
Jacobs, R.F., 93
Jacoby, G.A., 481
Jacqz-Aigrain, E., 87
Janney, A., 221
Jenkins, S.G., 51
Johnson, J., 9
Johnson, W., 295
Joly, J.R., 89S, 295
Jones, P.D., 235S
Jones, R.N., 23, 25, 81, 101, 103S, 143,
 271, 279, 363, 367, 381, 385, 413,
 489, 495
Kageyama, T., 215S
Kanra, G., 185S
Kapell, K., 87S
Kasse, M.C., 87
Kaufman, C., 45S
Kawagoe, H., 215S
Kazmierczak, A., 139S

Kearns, G.L., 93
 Keiser, J.F., 217, 309
 Kenny, M.T., 449
 Kernodle, D.S., 57
 Kessler, H.A., 87S
 Kiehn, T.E., 517
 Kiley, M.P., 333
 Kipp, J., 97S
 Kitani, T., 215S
 Klastersky, J., 165, 201S
 Klimm, K., 481
 Knapp, C.C., 511
 Koss, J., 77S
 Kuritzka, A.P., 129
 Labia, R., 139S
 Lancero, M.G., 17S
 Landry, M.L., 407
 Lee, C.F., 315
 Lee, C.-Y., 179S
 Lee, J.H., 175S
 Lee, M.-J., 179S
 Lehman, S.M., 463
 Lin, T.-Y., 179S
 Lipper, S.L., 333
 Lipson, S.M., 361
 Lisker, A., 319
 Liu, C., 17
 Lundström, I., 171
 Maccato, M., 189S
 MacDonald, J., 521
 MacLowry, J.D., 177
 Magalhaes, M., 35S
 Mahafzah, A.M., 407
 Marriott, D., 235S
 Martens, M.G., 189S
 Martinez, O.V., 193
 Masaoka, T., 215S
 Massanari, R.M., 295
 Mathew, A., 9
 Mathew, T.K., 205
 Mathewson, J.J., 139
 Mathieu, H., 87
 Matsen, J.M., 7S
 mejia de R., G.I., 51S
 Mendelman, P.M., 445
 Mendelson, J., 473
 Miller, P., 209S
 Moellering Jr., R.C., 149, 481
 Molinari, G., 53S
 Montelli, A.C., 35S
 Morahan, M., 473
 Moyer, N., 295
 Müller, S., 97S
 Mumtaz, G., 65S
 Munro, R., 159S
 Nagai, K., 215S
 Neihart, R.E., 17
 Nelson, J.A., 107
 Neu, H.C., 23, 103S, 107S, 109S, 119, 243,
 249S, 257, 283, 343, 441, 477
 Nevel, C.A., 211
 Nichols, R.L., 195S
 Nilsson, L.E., 171
 Niu, W.-W., 243, 477
 Notario, R., 45S
 Novick Jr., W.J., 149
 Obeid, F.N., 113
 O'Hanley, P., 133
 Ongsansoy, E.G., 205
 Osborne, T.A., 287
 Ostrowski, S., 291
 Packer, R.R., 385
 Paglia, P., 53S
 Pai, S.D., 175S
 Pant, C.R., 133
 Paolasso, R., 45S
 Papasian, C.J., 189
 Parkhurst, G.W., 107
 Pate, M.S., 433
 Pechinot, A., 139S
 Perez, S., 45S
 Peter, K., 131S
 Peterie, J.D., 101
 Peterson, E.M., 269
 Pfaller, M.A., 1, 295, 337, 413, 467, 489
 Phillips, G., 429
 Phillips, P., 429
 Plorde, J.J., 303
 Polsky, B., 517
 Portnoy, J., 473
 Porven, G., 45S
 Qadri, S.G.M., 291
 Qadri, S.M.H., 291
 Reiszner, E., 149
 Rice, D.H., 315
 Riddle, G., 189S
 Ridgway, G.L., 65S
 Rimland, D., 123
 Rinaldi, M.G., 429
 Robbins, M.J., 65S
 Rossolini, G.M., 57S
 Rotstein, C., 157
 Saha, G., 283
 Sanders, C.V., 1S, 165, 221
 Sanghrajka, M., 65S
 Santos, J.I., 147S
 Sarachian, B., 45S
 Satta, G., 57S
 Saubolle, M.A., 457
 Sawai, T., 121S
 Saxon, B., 7S
 Schiro, D.D., 221
 Schito, G.C., 53S
 Schmitt, B.A., 107
 Schonberger, L.B., 333
 Scully, B.E., 257
 Secmeer, G., 185S
 Secor, S.L., 139
 Segreti, J., 87S, 253
 Sewell, D.L., 261, 457
 Shah, P.M., 97S
 Shatzler, K.L., 13S
 Shimada, K., 171S
 Siebor, E., 139S
 Sierra-Madero, J., 511
 Smith, D., 189S
 Smith, T.F., 5, 275
 Sonstein, S.A., 21S
 Sorensen, V.J., 113
 Speed, B.R., 235S
 Staneck, J.L., 449
 Starr, E., 211
 Stein, D.K., 221S
 Stevens, D.L., 73
 Stewart, J.A., 333
 Stille, W., 97S
 Stratton, C.W., 29S, 57, 165
 Strausbaugh, L.J., 261
 Subbarao, E.K., 327
 Sugar, A.L., 221S
 Surmont, I., 265
 Swenson, J.M., 13
 Tarim, O., 185S
 Telenti, A., 5
 Telzak, E.E., 517
 Thomson Jr., R.B., 287
 Thornsberry, C., 13
 Torney, H.L., 449
 Torres, J.R., 41S
 Trabulsi, L.R., 35S
 Travis, L.B., 177
 Trenholme, G.M., 87S, 107, 253
 Truant, A.L., 211
 Trujillo, H., 51S
 Tsolakis, M., 211
 Valentini, S., 57S
 Vanbosterhaut, B., 265
 Vandepitte, J., 265
 Van der Auwera, P., 165S
 Vandeven, J., 265
 Venezio, F.R., 13S
 Waites, K.B., 433
 Wallis, C.K., 303
 Waner, J.L., 327
 Washington, J.A., 413, 511
 Washton, H., 229S
 Wasilauskas, B.L., 39
 Wauters, G., 265
 Weckbach, L.S., 449
 Weeks, L.S., 29S, 57, 165
 Wells, D.L., 333
 Wellstood, S., 395
 Wendt, S.E., 315
 Wenzel, R.P., 1, 295, 337
 Weselowski, V., 77S
 Wey, S., 1
 Wiedemann, B., 131S
 Willey, S., 149
 Willoughby, P.B., 319
 Winsor Jr., D.K., 139
 Witebsky, F.G., 217, 309, 401
 Witwicki, E., 83S
 Wood, C.A., 261
 Wood, W.S., 429
 Wright, D.N., 7S
 Yamaguchi, A., 121S
 Yasunaga, K., 215S
 Yonezawa, T., 215S
 Young, L.S., 17S
 Yu, K.-W., 441
 Yu, P.K.W., 463

Subject Index to Volume 12

A549 cell culture
adenovirus infection detected via, 407

A16686
antibacterial activity of, 279

Abbott kit
HIV-1 antigen detected via, 319

Abcess
brain, *Mycoplasma hominis* associated with, 193
cutaneous, streptococcal, 189

Abcess model
rat peritoneal, cefotaxime efficacy assessed via, 149

Abdominal trauma
penetrating, antibiotic regimens against, 113

Acinetobacter anitratus
piperacillin/tazobactam against, 481

Acinetobacter baumanii
sulbactam/β-lactam antibiotics against, 165S

Acinetobacter calcoaceticus
lomefloxacin against, 45S
sulbactam/ampicillin against, 179S

Acinetobacter spp.
ampicillin resistance in, 249S
desacetylcephalotaxin against, 23, 119
lomefloxacin against, 1S, 77S, 221
MDL 19, 592 against, 441
sulbactam/cefoperazone against, 209S

Acquired immune deficiency syndrome (AIDS)
cryptococcal meningitis in, fluconazole against, 235S
fungal infections associated with, 221S
mycobacteremia as common feature of, 303

Mycobacterium avium in, lomefloxacin against, 17S
mycoses associated with, fluconazole against, 239S
Nocardia asteroides pneumonia in, 517

Aculeacin A
antifungal activity of, 1

Acyclovir
in humans, peak serum levels achievable, 5

AD169 strain
cytomegalovirus, antiviral activity against, 5

Adenoclone enzyme immunoassay kit
adenovirus isolates identified via, 361, 407

Adenosine triphosphate (ATP)
assay of based on ampicillin susceptibility tests, *Escherichia coli* spheroplast formation and, 171

Adenoviruses
diagnosis of infection by, 407
identification of, 361
respiratory syncytial virus in conjunction with, 327

Agar dilution screening

inhibitory activity of antibacterial drugs assessed via, 33, 39, 51
staphylococcal resistance to penicillase-resistant penicillins assessed via, 385

Agrobacterium radiobacter
bacteremia, foreign body removal as therapy for, 351

AIDS, *See* Acquired immune deficiency syndrome

Amikacin
antibacterial activity of, 157

Aminoglycosides
nephrotoxicity and ototoxicity of, 9

Amoxicillin
antibacterial activity of, 57S, 65S

amp D gene
inactivation of, β-lactamase induction and, 131S

Amphotericin B
antibacterial activity of, 1
antifungal activity of, 235S
intolerance to, 17

Amphotericin B methyl ester
against fungal infections, 17

Ampicillin
antibacterial activity of, 9, 87, 93, 171
resistance to, 159S, 181, 249S, 283

Ampicillin/sulbactam
antibacterial activity of, 9, 39, 117S, 421

AMS-Vitek GNI card
gram-negative bacilli identified via, 211

Antibiograms
of morphological variants of blood culture isolates, clinically significant differences in, 177

Arthritis
septic, 189, 193

Aspergillosis
azoles against, 221S
fluconazole against, 239S

Aspergillus spp.
fluconazole against, 239S
in immunocompromised hosts, 221S

ATP, *See* Adenosine triphosphate

Autobac 18 chamber cuvette
gram-negative bacilli identified via, 211

Azlocillin
resistance to, 283

Azole antifungal agents
activity of, 221S, 467

Aztreonam
activity of not enhanced by blood product medium supplements, 149
lomefloxacin activity greater than, 221
resistance to, 283

Bacillus cereus
penicillinase, in teicoplanin bioassay, 449

Bacillus spp.
ramoplanin against, 279

Bacillus subtilis

ATCC 6633, as bioassay organism, 235
in teicoplanin bioassay, 449

Bactec blood cultures
evaluation of, 303
microbial dialysates inoculated into, 457

mycobacterial DNA probe analysis and, 309

mycobacterial inter-bottle transfer in, 401

Mycobacterium avium complex identified in, 217

Staphylococcus aureus identified in, 205

Bacteremia
Agrobacterium radiobacter, 351
CDC Group Ve-2, 351
gram-negative, cefotaxime against, 107
Mycobacterium avium complex, 309

Bacteroides bivius
cefotaxime-desacetylcefotaxime against, 45

metronidazole/gentamicin against, 189S
sulbactam/ampicillin against, 189S

Bacteroides capillosus
cefotaxime-desacetylcefotaxime against, 45

Bacteroides disiens
cefotaxime-desacetylcefotaxime against, 45

Bacteroides distasonis
cefotaxime against, 39
cefotaxime-desacetylcefotaxime against, 39

Bacteroides fragilis
antibiotics against, 195S
cefoperazone against, 421
cefoperazone/sulbactam against, 421
cefotaxime against, 45, 165
cefotaxime-desacetylcefotaxime against, 23, 33, 39, 45, 120, 165

cefotetan against, 39

cefoxatime against, 33

cefoxitin against, 33, 39

cephalosporinases produced by, cefmetazole inhibition of, 367

desacetylcefotaxime against, 33, 45, 165

lomefloxacin against, 103S

piperacillin/tazobactam against, 481, 489

resistance in, 117S, 159S, 249S

sulbactam/ampicillin against, 179S

Bacteroides melaninogenicus
cefotaxime-desacetylcefotaxime against, 45

β-lactamase production in, penicillin inactivated by, 477

Bacteroides ovatus
cefotaxime-desacetylcefotaxime against, 33

cefoxitin against, 33

Bacteroides spp.
cefoperazone against, 421

cefoperazone/sulbactam against, 421

cefotaxime-desacetylcefotaxime against, 33

cefoxitin against, 33
lomefloxacin against, 65S
resistance in, 159S, 249S

Bacteroides thetaiotamicron
cefotaxime against, 39
cefotaxime-desacetylcefotaxime against, 33, 39, 120
cefoxitin against, 33

Bacteroides vulgatus
cefotaxime-desacetylcefotaxime against, 33
cefoxitin against, 33

Blastocystis hominis
detection of in diarrheal stools, 291

BMY 28142
against respiratory infections, 257

Bone marrow transplant
allogeneic, invasive hyalohyphomycosis associated with, 429

Brain abscesses
Mycoplasma hominis associated with, 193

Branhamella catarrhalis
cefmetazole against, 367
cefotaxime against, 165
identification of, 130
lomefloxacin against, 45S, 221, 437
novobiocin against, 363
SM-7338 against, 271

Brazilian purpuric fever
PBP profiles of *Haemophilus* spp. associated with, 445

Broth microdilution method
Bacteroides susceptibility assessed via, 421
cefotaxime activity assessed via, 81
cefotaxime-desacetylcefotaxime activity assessed via, 81
cefuroxime activity assessed via, 517
desacetylcefotaxime activity assessed via, 81
in vitro susceptibility testing using, 1
lomefloxacin activity assessed via, 1S
quality control limits for, 413
SM-7338 stability assessed via, 271
staphylococcal resistance to penicillins-assistant penicillins assessed via, 385
terconazole activity assessed via, 467

B virus
cell culture contamination by, 333

Campylobacter jejuni
lomefloxacin against, 65S

Campylobacter pylori
lomefloxacin against, 35S

Cancer patients
infections in, sulbactam/ cefoperazone against, 209S

Candida albicans
identification of, 521
nosocomial isolates of, antifungal agents against, 1
terconazole against, 467

Candida guillermondi
nosocomial isolates of, antifungal agents against, 1

Candida krusei

nosocomial isolates of, antifungal agents against, 1

Candida lusitaniae
nosocomial isolates of, antifungal agents against, 1

Candida parapsilosis
nosocomial isolates of, antifungal agents against, 1
terconazole against, 467

Candida rugosa
nosocomial isolates of, antifungal agents against, 1

Candida spp.
fluconazole against, 239S
in immunocompromised hosts, 221S

Candida tropicalis
identification of, 521
nosocomial isolates of, antifungal agents against, 1
terconazole against, 467

Candidiasis
fluconazole against, 229S
mucocutaneous, in AIDS, 221S

Carbohydrate fermentation testing
gonococci identified via, 129

Carumonam
resistance to, 283

Catheterization
urinary, coagulase-negative staphylococci associated with infection associated with, 123

CDC Group Ve-2 bacteremia
antibiotic therapy against, 351

CDC reagent
adenovirus infection detected via, 407

Cefazolin
in teicoplanin bioassay, 449

Cefepime
antibacterial activity of, 343
against respiratory infections, 257

Cefmetazole
antibacterial activity of, 367

Cefoperazone
antibacterial activity of, 143, 209S, 421
metabolism of, 25
resistance to, 283

Cefoperazone/sulbactam
antibacterial activity of, 250S, 421

Cefoxorime
antibacterial activity of, 517

Cefotaxime
antibacterial activity of, 33, 35S, 45, 57, 67, 81, 87, 93, 101, 107, 119, 149, 165, 221, 337
resistance to, 283

Cefotaxime-desacetylcefotaxime
antibacterial activity of, 23, 33, 39, 51, 57, 67, 73, 81, 87, '65

Cefotetan
antibacterial activity of, 39

Cefotiam
activity of not enhanced by blood product medium supplements, 149

Cefoxitin
antibacterial activity of, 33, 39, 117S, 367
against penetrating abdominal trauma, 113
resistance to, 153S, 249S

Cefpirome
antibacterial activity of, 337, 343

Ceftazidime
antibacterial activity of, 143, 157, 221, 243, 337, 343, 489
resistance to, 283
in teicoplanin bioassay, 449

Ceftizoxime
antibacterial activity of, 39
resistance to, 283

Ceftriaxone
metabolism of, 25
resistance to, 283
in teicoplanin bioassay, 449

Cefuroxime
antibacterial activity of, 65S
in teicoplanin bioassay, 449

Cell culture
respiratory syncytial virus identified via, 327

Cellulitis
streptococcal, 357

Centrifugation culture
adenoviral isolates detected via, 407
herpes simplex virus detected via, 315

Centrifugation-Oxoid system
for microbial detection in dialysates, 457

Cephalexin
resistance to, 181

Cephaloglycin
metabolism of, 25

Cephalosporinases
cefmetazole inhibition and, 367
β-lactamase inhibition and, 121S, 249S

Cephalothin
antibacterial activity of, 119
metabolism of, 25

Cephamycins
antibacterial activity of, 367

Cephaphirin
antibacterial activity of, 119
metabolism of, 25

CGP 31608
resistance to, 283

Chemiluminescence assay
luminol-enhanced, sulbactam activity assessed via, 139S, 147S

Children
bacterial infections in, drug therapy for, 93

Chlamydia trachomatis
in conjunctival specimens, identification of, 133
lomefloxacin against, 65S, 83S, 87S, 103S

Chloramphenicol
antibacterial activity of, 39, 117S
metabolism of, 25

Chloramphenicol succinate
antibacterial activity of, 93

Cinoxacin
metabolism of, 25

Ciprofloxacin
antibacterial activity of, 17S, 29S, 65S, 83S, 87S, 93S, 243, 253, 433

Citrobacter freundii
cephalosporinase, 121S, 249S

Citrobacter spp.
lomefloxacin against, 51S, 181

Clavulanate
antibacterial activity of, 511
resistance to, 283

Clindamycin
antibacterial activity of, 39, 117S
against penetrating abdominal trauma, 113
resistance to, 153S, 249S

Clostridium difficile
colitis associated with, detection of, 291
lomefloxacin against, 65S

Clostridium perfringens
lomefloxacin against, 65S

Clostridium spp.
resistance in, 117S, 159S, 249S

Clotrimazole
antibacterial activity of, 467

CMV, see *Cytomegalovirus*

Coccidioides immitis
fungal infections caused by, treatment of, 17

Coccidioidomycosis
in AIDS, 221S

Colitis
antibiotic-associated, detection of, 291

Combination antibiotic therapy
against penetrating abdominal trauma, 113

Corynebacterium jeikeium
lomefloxacin against, 13S
prosthetic valve endocarditis, diphtheroid, 265
ramoplanin against, 279

Cotrimoxazole
antibacterial activity of, 57S, 201S

Coulter kit
HIV-1 antigen detected via, 319

Cryptococcosis
azoles against, 221S
fluconazole against, 239S

Cryptococcus neoformans
fluconazole against, 239S

CS-1170
antibacterial activity of, 367

Cystic fibrosis
Pseudomonas isolates from patients with, 343

Cytocholasin B
polymorphonuclear leukocyte activity measurement and, 199

Cytomegalovirus (CMV)
antiviral activity against, 5
detection of, correlation of urine pH with, 275
respiratory syncytial virus identified in conjunction with, 327

Cytopathic effect
adenovirus associated, 361

Cytotoxic assay
for detection of antibiotic associated colitis, 291

Desacetylcefotaxime
antibacterial activity of, 33, 39, 45, 67, 81, 87, 93, 119, 143, 165
metabolism of, chemotherapy and, 25

Desacetylcephalothin
antibacterial activity of, 119

DHPG, see *Ganciclovir*

Diabetes mellitus
foot ulcers in, bacterial infection associated, 33

Dilution susceptibility testing
of penicillinase-resistant penicillin isolates, 385
of piperacillin/tazobactam, 495

Diphtheroids
Group JK, prosthetic valve endocarditis due to, 265

Direct immunofluorescent antibody staining
bacteria in conjunctival specimens identified via, 133
herpes simplex virus identified via, 315

Disk diffusion testing
cefotaxime activity assessed via, 81
cefotaxime-desacetylcefotaxime activity assessed via, 23, 67, 73, 81
cefuroxime assessed via, 517
SM-7338 stability assessed via, 271
staphylococcal resistance to penicillinase-resistant penicillins detected via, 381, 385

DNA gyrase
in bacterial resistance, 109S, 249S

DNA hybridization studies
of nucleotide sequence homologous to to Tn1545 transposon, 13

DNA probes
bacteria in conjunctival specimens identified via, 133
mycobacterial analysis via, 309
technology and medical applications of, 525

Doxycycline
antibacterial activity of, 87S

Dupont kit
HIV-1 antigen detected via, 319

E-1040
antibacterial activity of, 343

Echinocandin B
LY121019 as novel analog of, 1

Echoviruses
respiratory syncytial virus identified in conjunction with, 327

Empyema
streptococcal, 189

Endocarditis
combination therapy against, 9
native valve, staphylococcal, 261
prosthetic valve, *Corynebacterium* associated, 265
sulbactam/ampicillin against, 179S

Endometritis, post-Cesarean section
metronidazole/gentamicin against, 189S, 250S
sulbactam/ampicillin against, 189S, 250S

Enteritis
lomefloxacin against, 181

Enterobacter cloacae
cefotaxime-desacetylcefotaxime against, 73
sulbactam/ampicillin against, 179S

sulbactam/β-lactam antibiotics against, 165S

Enterobacteriaceae
cefepime against, 257
cefotaxime-desacetylcefotaxime against, 25, 120
cefmetazole against, 367
cefotaxime against, 165
lomefloxacin against, 1S, 7S, 17S, 35S, 41S, 45S, 51S, 52S, 57S, 65S, 77S, 97S, 103S, 221
MDL 19,592 against, 441
piperacillin/tazobactam against, 481, 489
QA-241 against, 243
quinolones against, 201S
sulbactam against, 139S
ticarcillin/clavanulate against, 511

Enterobacter spp.
lomefloxacin against, 51S

Enterococci
lomefloxacin against, 45S, 57S, 104S
MDL 19,592 against, 441
ramoplanin against, 279
SM-7338 against, 271

Enterococcus faecalis
ampicillin/sulbactam against, 9
cefotaxime against, 149
lomefloxacin against, 65S, 77S, 97S
metronidazole/gentamicin against, 189S
sulbactam/ampicillin against, 189S

Enterococcus faecium
ampicillin/sulbactam against, 9

Enterocolitis
infective, sulbactam/ampicillin against, 179S

Enzyme immunoassays
for detection of HIV-1, 319

Enzyme immunoassay transport medium
special, replacement of by standard
viral transport medium in Herp-check antigen detection test, 473

Eosin-methylene blue agar
Salmonella and *Shigella* recovery from, 463

Erythromycin
antibacterial activity of, 65S, 89S, 93S, 433
resistance to, 153S

Escherichia coli
ampicillin against, 87
cefotaxime against, 101
cefotaxime-desacetylcefotaxime against, 73
cephalothin against, 119
cephaphirin against, 119
ciprofloxacin against, 29S
lomefloxacin against, 29S, 51S, 57S, 65S, 97S, 181
metronidazole/gentamicin against, 189S
mezlocillin against, 157
piperacillin/tazobactam against, 495
polymorphonuclear leukocyte activity measurement and, 199
QR-241 against, 243
resistance in, 185S, 249S
spheroplast formation in, ampicillin effect on, 171
sulbactam against, 139S

sulbactam/ampicillin against, 179S, 189S
 sulbactam/β-lactam antibiotics against, 165S
 ticarcillin-clavulanic acid against, 157

FCE-22101
 antibacterial activity of, 143

Fleroxacin
 antibacterial activity of, 143, 221

Fluconazole
 antifungal activity of, 229S, 235S, 239S, 250S
Flucytosine
 antifungal activity of, 235S

5-Fluorocytosine
 antibacterial activity of, 1

Fluoroquinolones
 resistance to, 109S

Fosfomycin
 antibacterial activity of, 367

Fungus ball formation
 in preformed pulmonary cavity, as human mycosis, 429

Fungal infections
 fluconazole against, 229S
 in immunocompromised hosts, treatment of, 221S

Fungemia
 fluconazole against, 239S

Fusarium spp.
 in immunocompromised hosts, 221S

Fusobacterium spp.
 resistance in, 117S, 249S

Ganciclovir (DHPG)
 in humans, peak serum levels achievable in, 5

Gastroenteritis
 sulbactam/ampicillin against, 175S

Genitourinary tract
 manipulations of, sepsis following, 193

Gen-Probe Rapid Diagnostic System for *Mycobacterium avium* complex, 217, 309

Gentamicin
 antibacterial activity of, 35S, 51, 157, 221, 243
 against penetrating abdominal trauma, 113
 resistance to, 153S

Germ-tube test
Candida albicans identified via, 521

Giardia lamblia
 detection of in diarrheal stools, 291

Gonococci
 identification of, 129
 lomefloxacin against, 89S
 piperacillin/tazobactam against, 495

Gonorrhea
 identification of, 129

Granulocytopenia
 bacterial infections in, treatment of, 201S

Haemophilus aegyptius
 PBP analysis of, 445

Haemophilus ducreyi

lomefloxacin against, 83S, 103S
Haemophilus influenzae
 cefmetazole against, 367
 cefotaxime against, 165
 cefotaxime-desacetylcefotaxime against, 120
 lomefloxacin against, 45S, 89S, 104S, 221, 437
 novobiocin against, 363
 PBP analysis of, 445
 piperacillin/tazobactam against, 495
 QR-241 against, 243
 sulbactam/ampicillin against, 179S
 sulbactam/β-lactam antibiotics against, 165S

Haemophilus spp.
 lomefloxacin against, 65S

HEK cell culture
 adenovirus infection detected via, 407

Hematologic diseases
 infections in, sulbactam/cefoperazone against, 215S

Hemorrhage
 intracerebral, varicella associated, 357

HEP-2 cell culture
 adenovirus infection detected via, 407

Herpcheck antigen detection test
 herpes simplex virus detected via, 473

Herpes simplex virus (HSV)
 characterization of, 197
 detection of, 315, 473
 monoclonal antibody typing reagents for, 269
 respiratory syncytial virus identified in conjunction with, 327

Herpesvirus simiae
 cell culture contamination by, 333

Histoplasmosis
 in AIDS, 221S
 disseminated progressive, amphotericin B methyl ester against, 17

HIV, See Human immunodeficiency virus

HRE-664
 antibacterial activity of, 143

HSV, See Herpes simplex virus

Human immunodeficiency virus (HIV)
 detection of, 319
 as underlying risk factor, cefepime therapy for respiratory infections and, 257

Hyalohyphomycosis
 invasive, of great toe, 429

Hydrogen assay
 molecular, based on ampicillin susceptibility tests, *Escherichia coli* spheroplast formation and, 171

Imipenem
 antibacterial activity of, 117S, 143, 221, 243, 271, 337, 489, 421
 metabolism of, 25
 resistance to, 283

Immunocompromised patients
 cryptococcal infections in, fluconazole against, 250S
 fungal infections in, treatment of, 221S

Immunofluorescence

adenovirus infection detected via, 407
 respiratory syncytial virus identified via, 327

Influenza
 respiratory syncytial virus identified in conjunction with, 327

Intrathoracic infection
 sulbactam/ampicillin against, 185S

Isolator/BACTEC 12B blood culture medium
 evaluation of, 303

Isolator/Middlebrook agar blood culture medium
 evaluation of, 303

IsoVitaleX supplement
 SM-7338 stability in, 271

Ketoconazole
 antibacterial activity of, 1

Klebsiella oxytoca
 mezlocillin against, 157
 piperacillin against, 157
 ticarcillin against, 157

Klebsiella pneumoniae
 cefotaxime against, 101
 cefotaxime-desacetylcefotaxime against, 73
 cephalothin against, 119
 cephaphirin against, 119
 ciprofloxacin against, 29S
 lomefloxacin against, 29S

Klebsiella spp.
 lomefloxacin against, 51S
 resistance in, 153S, 249S

β-Lactamase
 Class I, mutants derepressed for, 511
 enterococcal production of, ampicillin/sulbactam against, 9
 induction of, in gram-negative bacteria, 131S
 inhibitors, antibacterial activity of, 283, 477, 481, 495
 inhibitors, resistance and, 109S, 121S, 153S, 249S
 staphylococcal, production of, 57

β-Lactam
 antibacterial activity of, 57S, 165S, 143
 resistance to, 109S
 teicoplanin bioassay in presence of, 235, 449

Lactose peptone broth
Escherichia coli in, 171

Latex agglutination test
 antibiotic-associated colitis detected via, 291
 rotavirus detected in stool specimens via, 139

Salmonella detected via, 463

Shigella detected via, 463

Legionella bozemani
 ciprofloxacin against, 93S
 erythromycin against, 93S
 lomefloxacin against, 93S

Legionella dumoffi
 ciprofloxacin against, 93S
 erythromycin against, 93S

lomefloxacin against, 89S, 93S
Legionella hackeliae
 ciprofloxacin against, 93S
 erythromycin against, 93S
 lomefloxacin against, 93S
Legionella longbeachae
 ciprofloxacin against, 93S
 erythromycin against, 93S
 lomefloxacin against, 93S
Legionella maceachernii
 ciprofloxacin against, 93S
 erythromycin against, 93S
 lomefloxacin against, 93S
Legionella micdadei
 ciprofloxacin against, 93S
 erythromycin against, 93S
 lomefloxacin against, 93S
Legionella pneumophila
 ciprofloxacin against, 93S
 erythromycin against, 93S
 lomefloxacin against, 89S, 93S
 serogroup 1, epidemiology of, 295
Legionella spp.
 lomefloxacin against, 45S, 89S, 93S, 103S, 104S
Legionella wadsworthii
 ciprofloxacin against, 93S
 erythromycin against, 93S
 lomefloxacin against, 93S
 Leukopenia
 sulfadiazene-associated, 517
 Lincinoids
 resistance to, 109S
Listeria monocytogenes
 MDL 19,592 against, 441
 ramoplanin against, 279
Listeria spp.
 lomefloxacin against, 77S
 Lomefloxacin
 antibacterial activity of, 1S, 7S, 13S, 17S, 21S, 29S, 35S, 41S, 45S, 51S, 77S, 83S, 87S, 89S, 93S, 97S, 103S, 221, 433, 437
 multiple doses of, safety and tolerance of, 181
 postantibiotic effect of, 52S, 57S, 65S
 Lung disease
 chronic, cefipime against, 257
 LY121019
 antibacterial activity of, 1
 Lysostaphin susceptibility test
Staphylococcus aureus identified via, 205
 M7H11/BHI biphasic medium
 evaluation of, 303
 Macrolides
 resistance to, 109S
 MDL 19,592
 antibacterial activity and β -lactamase stability of, 441
 MDL62198
 antibacterial activity of, 279
 Meningitis
 bacterial, drug therapy against, 93
 cryptococcal, fluconazole against, 229S, 235S
 Meningococci

cefotaxime-desacetylcefotaxime against, 120
 Meniscal tear
 acute, as predisposing factor for septic arthritis, 189
 Meritec-Rotavirus assay
 rotavirus detected in stool specimens via, 139
 4-Methylumbelliferyl-N-acetyl- β -galactosaminide
Candida albicans identification via, 521
 Metronidazole
 antibacterial activity of, 39, 117S, 159S, 421
 metabolism of, 25
 Metranidazole/gentamicin
 antibacterial activity of, 189S, 250S
 Mezlocillin
 antibacterial activity of, 157
 resistance to, 283
 in teicoplanin bioassay, 449
 Miconazole
 antibacterial activity of, 467
 Microscan Combo Plus Panel
 gram-negative bacilli identified via, 211
 MICs, see Minimum inhibitory concentrations
 Minimum inhibitory concentrations (MICs)
 for ampicillin, 159S, 171
 for ampicillin/sulbactam, 9
 for cefazolin, 57
 for cefmetazole, 367
 for cefoperazone, 421
 for cefotaxime, 33, 51, 57, 81, 87, 93, 101, 107, 165, 337
 for cefotaxime-desacetylcefotaxime, 33, 45, 81, 165
 for cefoxitin, 159S, 489
 for cefpirome, 337
 for ceftazidime, 337
 for cefuroxime, 517
 for ciprofloxacin, 29S, 93S, 433
 for clindamycin, 159S
 for desacetylcefotaxime, 57, 165
 for erythromycin, 93S, 433
 for gentamicin, 81
 for imipenem, 337
 lomefloxacin, 1S, 7S, 13S, 17S, 29S, 35S, 41S, 45S, 51S, 52S, 57S, 65S, 77S, 83S, 87S, 89S, 93S, 97S, 104S, 181, 221, 433, 437
 for LY121019, 1
 for lysostaphin, 205
 for MDL 19,592, 441
 for metronidazole, 159S
 for minocycline, 253
 for novobiocin, 363
 for penicillin, 13
 for piperacillin, 337, 489, 511
 for piperacillin/tazobactam, 489, 495, 511
 for QR-241, 243
 quality control limits for broth microdilution testing and, 413
 for ramoplanin, 279
 for rifampin, 253
 for sulbactam, 139S
 for sulbactam/ampicillin, 159S
 for tazobactam, 495, 511
 for teicoplanin, 385
 for terconazole, 467
 for tobramycin, 81, 337
 Minocycline
 antistaphylococcal activity of, 253
 Miokamycin
 antibacterial activity of, 57S
 Monoclonal antibodies
 to early and late antigens of cytomegalovirus, 5
 Monoclonal antibody typing reagents
 fluorescent, for identification of adenoviral isolates, 407
 for herpes simplex virus, 269, 315
Legionella pneumophila serogroup 1 epidemiology studied via, 295
Moraxella catarrhalis
 SM-7338 against, 271
Morganella morganii
 cefotaxime-desacetylcefotaxime against, 119
 piperacillin/tazobactam against, 495
 Moxalactam
 in vitro activity of not augmented by serum, 149
 MRC-5 cell culture
 adenovirus infection detected via, 407
 MRS test
 sensitivity of to staphylococci, evaluation of, 395
 Mucormycosis
 fluconazole against, 239S
 Mueller-Hinton agar
 sheep blood added to, effect of on cephalosporin antibacterial activity, 149
 Mueller-Hinton II agar
 in teicoplanin bioassay medium, 235
 Mupirocin
 antibacterial activity of, 279
Mycobacterium avium
 detection of, 309
 inter-bottle transfer of, 401
 lomefloxacin against, 17S
 mycobacteremia associated with, 303
 simultaneous infection with *Mycobacterium intracellulare* in AIDS patient, 217
Mycobacterium fortuitum
 inter-bottle transfer of, 402
Mycobacterium haemophilum
 mycobacteremia associated with, 303
Mycobacterium intracellulare
 inter-bottle transfer of, 402
 simultaneous infection with *Mycobacterium avium* in AIDS patient, 217
Mycobacterium spp.
 lomefloxacin against, 45S
Mycobacterium tuberculosis
 detection of, 309
 inter-bottle transfer of, 401
 mycobacteremia associated with, 303
Mycoplasma hominis
 lomefloxacin against, 65S, 83S

sepsis caused by, in multiple trauma cases, 193

Mycoplasma pneumoniae
ciprofloxacin against, 433
erythromycin against, 433
lomefloxacin against, 433

Mycoplasma spp.
metronidazole/gentamicin against, 189S
sulbactam/ampicillin against, 189S

Mycoses
deep, fluconazole against, 239S
as public health problem, 21
systemic, diagnosis and therapy of, 455

Nafcillin
in teicoplanin bioassay, 449

Nalidixic acid
metabolism of, 25

Nasopharyngeal specimens
yielding respiratory syncytial virus,
multiple viral agents in, 327

Neisseria flavescens
identification of, 130

Neisseria gonorrhoeae
identification of, 129
lomefloxacin against, 35S, 45S, 83S,
103S, 221
piperacillin/tazobactam against, 495
QR-241 against, 243
SM-7338 against, 271
sulbactam/β-lactam antibiotics against,
165S

Neisseria lactamica
identification of, 129, 130

Neisseria meningitidis
identification of, 130
piperacillin/tazobactam against, 495

Neisseria sicca
identification of, 130

Neisseria spp.
cefmetazole against, 367
lomefloxacin against, 65S, 104S
novobiocin against, 363
SM-7338 against, 271

Neisseria subflava
identification of, 130

Neonates
bacterial infections in, drug therapy for,
87, 93

Netilmicin
antibacterial activity of, 57S, 210S

Neutropenia
bacterial infections in, treatment of,
201S
gram-positive bacteria associated with,
143

Neutrophils
killing of single microorganisms by,
measurement of, 199

NIH-ELISA assay, rotavirus detected in
stool specimens via, 139

Nocardia asteroides
pneumonia, cefuroxime against, 517

Norfloxacin
antibacterial activity of, 35S, 52S, 57S,
87S, 221

Novobiocin
antibacterial activity of, 363

NY-198
antibacterial activity of, 1S, 7S, 21S,
29S, 41S, 45S, 87S, 89S, 93S, 97S,
103S, 221, 437

Ofloxacin
antibacterial activity of, 52S, 65S, 221,
243

ORTHOProbe DNA probe test
gonococci identified via, 129

Osteoarthritis
as predisposing factor for septic arthritis, 189

Osteomyelitis
vertebral, staphylococcal, 261

Otitis media
sulbactam/ampicillin against, 179S

Oxoid system
for microbial detection in dialysates, 457

Oxytetracycline
antibacterial activity of, 65S

p24 antigen
HIV-1, detection of, 319

Papillomaviruses
characterization of, 197

Parainfluenza viruses
respiratory syncytial virus identified in
conjunction with, 327

PBP analysis
Haemophilus strain differentiation via,
445

Pediatric infections
sulbactam/ampicillin against, 179S, 185S

Pelvic inflammatory disease
Mycoplasma hominis associated with, 193

Pelvic trauma
sepsis following, 193

Penicillin
antibacterial activity of, 23, 157
β-lactamase inactivation of, 477
PBP analysis and, 445
resistance to, 13, 381, 385

Penicillinase
β-lactamase inhibition and, 121S
resistance to, 381, 385

Penicillin G
against enterococci, 9

Peptostreptococcus spp.
lomefloxacin against, 65S
sulbactam/ampicillin against, 179S

Peritoneal dialysis
continuous ambulatory, microbial detection
in effluents from, 457

Peritonitis
sulbactam/ampicillin against, 179S

Phosphonoformic acid
in humans, peak serum levels achievable in, 5

Piperacillin
antibacterial activity of, 117S, 157, 337,
481, 495
resistance to, 249S, 283, 477

Piperacillin/tazobactam
antibacterial activity of, 481, 489, 495,
511

Plaque reduction assay

antiviral activity against cytomegalovirus assessed via, 5

Pneumococci
resistance in, 13, 109S

Pneumonia
Legionella pneumophila serogroup 1, 295
Nocardia asteroides, in AIDS, 517
sulbactam/ampicillin against, 179S

Pneumonitis
hypersensitivity, as human mycosis,
429

Polio viruses
vaccine strain, respiratory syncytial virus identified in conjunction with, 327

Polyclonal antibody reagents
fluorescent, for identification of adenoviral isolates, 407

Polymerase chain reaction
amplified DNA probe, for identification of bacteria in conjunctival specimens, 133

Polymorphonuclear leukocytes
measurement of activity of, 199
sulbactam effect on function of, 139S,
147S

Primary rhesus monkey kidney cell cultures
B virus contamination of, 333

Prosthetic devices
clinical infections in setting of, staphylococcal, 261

Proteus mirabilis
lomefloxacin against, 51S
mezlocillin against, 157
sulbactam against, 139S
sulbactam/ampicillin against, 179S
ticarcillin against, 157
ticarcillin/clavulanic acid against, 157
trimethoprim resistance in, 153S

Proteus spp.
lomefloxacin against, 35S, 51S, 181

Proteus vulgaris
cefotaxime-desacetylcefotaxime against,
119
piperacillin/tazobactam against, 495

Providencia spp.
lomefloxacin against, 35S

Providencia stuartii
piperacillin against, 157
piperacillin/tazobactam against, 495
ticarcillin against, 157

Pseudomonas aeruginosa
amikacin against, 157
cefepime against, 257
cefoperazone against, 143
cefotaxime against, 107, 337
cefprome against, 337
ceftazidime against, 143, 157, 337
ciprofloxacin against, 29S
imipenem against, 143, 337
lomefloxacin against, 1S, 7S, 13S, 17S,
29S, 35S, 41S, 45S, 52S, 57S, 65S,
77S, 97S, 221
MDL 19,592 against, 441
piperacillin against, 157, 337
piperacillin/tazobactam against, 481
QR-241 against, 243

SM-7338 against, 271
subbactam/β-lactam antibiotics against, 165S
 ticarcillin against, 157
 tobramycin against, 337
Pseudomonas cepacia
 C-3 substituted cephalosporins against, 343
 decacetylcephotaxime against, 23, 119
 lomefloxacin against, 221
Pseudomonas spp.
 cefotaxime/desacetylcefotaxime/amino-glycosides against, 51
 lomefloxacin against, 17S, 21S, 45S, 51S, 104S
 ticarcillin/clavulanate against, 511
Pseudomonic acid
 antibacterial activity of, 279
Pyelonephritis
Mycoplasma hominis associated with, 193
Pyogenic infections
 streptococcal, 189

QA-241
 in vitro activity of, comparative, 243
Quinolones
 fluorinated, metabolism of, 25

Ramoplanin
 antibacterial activity of, 279
Resistance
 bacterial, to antibiotics, 109S, 117S, 153S, 159S, 249S
Respiratory syncytial virus (RSV)
 nasopharyngeal specimens yielding multiple viral agents in, 327
Respiratory tract infections
 cephalosporins against, 257
 lomefloxacin against, 181
 subbactam/ampicillin against, 171S, 175S
Restriction endonuclease analysis
 of plasmid DNA, epidemiology of *Legionella pneumophila* serogroup 1 studied via, 295
Rhinoviruses
 respiratory syncytial virus identified in conjunction with, 327
Rhizopus spp.
 in immunocompromised hosts, 221S
Rifampin
 antibacterial activity of, 65S, 89S, 253
 metabolism of, 25
 teicoplanin bioassay in presence of, 235, 449
RO 23-9424
 antibacterial activity of, 143
Rotavirus
 detection of, in stool specimens, 139, 291
Rotazyme II assay, rotavirus detected in stool specimens via, 139
RSV, *See* Respiratory syncytial virus

Salmonella enteritidis
 cefotaxime against, 101
 detection of in diarrheal stools, 291
Salmonella spp.
 detection of, 463
 lomefloxacin against, 51S, 181
 subbactam/ampicillin against, 179S
Salmonellosis
 systemic, subbactam/ampicillin against, 185S
SC-47111
 antibacterial activity of, 1S, 7S, 17S, 21S, 29S, 41S, 45S, 87S, 89S, 93S, 97S, 103S, 221, 437
Scopulariopsis brevicaulis
 invasive halohyphomycosis caused by, 429
Sepsis
 intraabdominal, subbactam/ampicillin against, 195S, 250S
Septicemia
 subbactam/ampicillin against, 175S, 179S
Serologic methods
 gonococi identified via, 129
Serratia marcescens
 cefotaxime against, 101
 cefotaxime/desacetylcefotaxime against, 73
 lomefloxacin against, 51S
 subbactam/β-lactam antibiotics against, 165S
Serum bactericidal activity
 as indicator of adequate antibiotic dosing, 101
Sexually transmitted diseases
 lomefloxacin against, 181
Shell vial cell culture
 assay based on, cytomegalovirus activity assessed via, 5, 275
Shigella boydii
 detection of in diarrheal stools, 291
Shigella sonnei
 subbactam/ampicillin against, 179S
Shigella spp.
 detection of, 463
 lomefloxacin against, 51S, 181
 piperacillin/tazobactam against, 495
Skeletal system infection
 subbactam/ampicillin against, 185S
Slime production
 by coagulase-negative staphylococci, implication of as virulence factor in urinary tract infections, 123
SM-7338
 in susceptibility testing media, stability of, 271
Soft tissue infections
 subbactam/ampicillin against, 179S, 185S
Staphylococci
 cefmetazole against, 367
 cefotaxime/desacetylcefotaxime combination against, 25
 clinically significant differences in anti-biograms and, 177
 contamination and, 205
 identification of, 211, 395
 lack of demographic characteristics or laboratory markers associated with, 123
 lomefloxacin against, 7S, 17S, 21S, 35S, 45S, 51S, 52S, 57S, 89S, 97S, 104S
 minocycline against, 253
 novobiocin against, 363
 piperacillin/tazobactam against, 481, 495
 resistance in, 109S, 381, 385
 SM-7338 against, 271
Staphylococcus aureus
 cefepime against, 257
 cefmetazole against, 367
 cefotaxime against, 57, 165
 cefotaxime-desacetylcefotaxime against, 57, 73
 cephalothin against, 119
 cephaphirin against, 119
 ciprofloxacin against, 29S
 desacetylcephalothin against, 119
 fosfomycin against, 367
 identification of, 205, 395
 lomefloxacin against, 29S, 41S, 57S, 65S, 97S, 221
 MDL 19,592 against, 441
 minocycline against, 253
 polymorphonuclear leukocyte activity measurement and, 199
 QR-241 against, 243
 resistance in, 385
 subbactam/ampicillin against, 179S
 subbactam/β-lactam antibiotics against, 165S
 ticarcillin/clavulanic acid against, 157
 vancomycin against, 157
Staphylococcus capitis
 ramoplanin against, 279
Staphylococcus epidermidis
 ciprofloxacin against, 29S
 lomefloxacin against, 13S, 29S, 41S, 51S, 221
 QR-241 against, 243
 resistance in, 385
 slime production by, 123
 subbactam/ampicillin against, 179S
 ticarcillin/clavulanic acid against, 157
 vancomycin against, 157
Staphylococcus haemolyticus
 resistance in, 385, 385
Staphylococcus saprophyticus
 not implicated as pathogen in urinary tract infections, 123
 lomefloxacin against, 51S
 ramoplanin against, 279
Staphylococcus warneri
 native valve endocarditis due to, 261
 vertebral osteomyelitis due to, 261
Stool specimens
 rotavirus detection in, 139
Salmonella detection in, 463
Shigella detection in, 463
Streptococci
 cefmetazole against, 367
 cefotaxime/desacetylcefotaxime against, 120
 lomefloxacin against, 21S, 35S, 41S, 45S, 51S, 77S
 MDL 19,592 against, 441
 neonatal infections caused by, 87
 SM-7338 against, 271
Streptococcus anginosus
 septic arthritis of knee caused by, 189
Streptococcus faecalis
 QR-241 against, 243
Streptococcus pneumoniae

cefepime against, 257
 cefotaxime against, 165
 cefotaxime-desacetylcefotaxime against, 120
 ciprofloxacin against, 29S
 lomefloxacin against, 29S, 65S
 MDL 19,592 against, 441
 Minnesota strain, multiresistant, 13
Streptococcus pyogenes
 ciprofloxacin against, 29S
 lomefloxacin against, 29S
 MDL 19,592 against, 441
 sulbactam/ampicillin against, 179S
Sulbactam
 antibacterial activity of, 165S
 polymorphonuclear leukocyte function and, 147S
 resistance to, 283
 secondary modes of action for, 139S
Sulbactam/ampicillin
 antibacterial activity of, 159S, 171S, 175S, 179S, 185S, 189S, 250S
 polymorphonuclear leukocyte function and, 147S
 resistance to, 153S
Sulbactam/cefoperazone
 antibacterial activity of, 209S, 215S
Sulfadiazine
 side effects of, 517
Sulfamethoxazole
 antibacterial activity of, 65S
Sulfonamides
 metabolism of, 25
 resistance to, 109S
Sultamicillin
 antibacterial activity of, 175S
Surgical wound infection
 sulbactam/ampicillin against, 175S
Sykes Class I enzymes
 produced by gram-negative bacteria, ticarcillin stable in presence of, 157
Tazobactam
 antibacterial activity of, 481, 489, 495, 511
 emergence of resistance prevented by, 477
Teicoplanin
 antibacterial activity of, 385
 bioassay for, 235, 449
Terconazole
 antibacterial activity of, 467
Tetracyclines
 antibacterial activity of, 253
 resistance to, 13, 109S
Theophylline
 lomefloxacin administered with, 181
Thermonuclease test
 rapid, *Staphylococcus aureus* identification via, 205
Thrombocytopenia
 varicella associated intracerebral hemorrhage in absence of, 357
Thrombophlebitis
 septic, in multiple trauma, 193
Ticarcillin
 antibacterial activity of, 117S, 157
 resistance to, 283
 in teicoplanin bioassay, 449
Ticarcillin/clavulanate
 antibacterial activity of, 421, 511
Ticarcillin/clavulanic acid
 antibacterial activity of, 157, 221, 489
Time-kill studies
 ampicillin/sulbactam activity assessed via, 9
Tissue culture passage
 serial, for identification of bacteria in conjunctival specimens, 133
Tn1545 transposon
 nucleotide sequence homologous to, 13
Tobramycin
 antibacterial activity of, 51, 337, 343
Toenail infection
 as human mycosis, 429
Tonsillitis
 exudative, hemolytic streptococci in, 477
 sulbactam/ampicillin against, 179S
Trachoma
 epidemiology of, 133
Trichosporon spp.
 in immunocompromised hosts, 221S
Trimethoprim
 antibacterial activity of, 57S, 65S
 resistance to, 109S, 153S
Trimethoprim/sulfamethoxazole
 antibacterial activity of, 201S, 221, 253
Trough serum
 bactericidal activity of, 101
Typhoid fever
 sulbactam/ampicillin against, 175S
Ureaplasma spp.
 metronidazole/gentamicin against, 189S
 sulbactam/ampicillin against, 189S
Ureaplasma urealyticum
 lomefloxacin against, 65S, 83S
Urinary tract infections
 coagulase-negative staphylococci as cause of, 123
 lomefloxacin against, 181
 sulbactam/ampicillin against, 171S, 175S, 179S
Urine
 pH, cytomegalovirus detection associated with, 275
Vaccines
 technological advances in development of, 289
Vancomycin
 antibacterial activity of, 157, 253, 265, 279, 385
Varicella zoster virus (VZV)
 detection of, 287, 288
 intracerebral hemorrhage associated with, 357
Vibrio spp.
 lomefloxacin against, 65S
Viral transport medium
 standard, in Herpcheck antigen detection test, 473
Virogen Rotatest assay, rotavirus detected in stool specimens via, 139
Xanthomonas maltophilia
 resistance in, 283
Yersinia spp.
 lomefloxacin against, 181
YTR 830
 antibacterial activity of, 481, 489, 495



